New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"

Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.

Morten Søgaard is moving from one US coast to another, as he makes a switch from Pfizer to Astellas Gene Therapies | Photo: Jens Panduro

Morten Søgaard is packing up shop in New York, where he has spent the past 12 years at pharmaceutical giant Pfizer. He’s now replacing the East Coast with the West Coast, as he joins the San Francisco-based development department of Japanese Astellas Gene Therapies.

He will lead a team of around 100 people, most of whom are also situated on the Western Seaboard of the US, with some members in Tokyo, Japan, where Astellas is headquartered.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs